2H-1,4-苯并噁嗪-3(4H)-酮,2-[2-[[(1,1-二甲基乙基)二甲基甲硅烷基]氧代]乙基]- | 191097-22-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 中文名称: 2H-1,4-苯并噁嗪-3(4H)-酮,2-[2-[[(1,1-二甲基乙基)二甲基甲硅烷基]氧代]乙基]-
• 英文名称: 2-(2-tert-butyldimethylsiloxyethyl)-4H-benzo[1,4]oxazin-3-one
• 英文别名: 2-(2-tert-butyldimethylsiloxyethyl)-3,4-dihydro-3-oxo-2H-1,4-benzoxazine；2H-1,4-benzoxazin-3(4H)-one, 2-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-；2-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-4H-1,4-benzoxazin-3-one
• CAS: 191097-22-0
• 化学式: C₁₆H₂₅NO₃Si
• 分子量: 307.465
• InChiKey: HRRLOYAIEBAUHR-UHFFFAOYSA-N

物化性质

• 沸点：
  396.9±35.0 °C(Predicted)
• 密度：
  1.029±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2H-1,4-苯并噁嗪-3(4H)-酮,2-[2-[[(1,1-二甲基乙基)二甲基甲硅烷基]氧代]乙基]- 以98%的产率得到4-氯甲基联苯
  参考文献：
  名称：

  Benzoxazine antimicrobial agents

  摘要：

  该发明涉及一般式为：##STR1##的苯并噁嗪和吡啶噁嗪抗菌化合物，其中基团Q是如本文所述的融合苯或融合吡啶基团，含有这些化合物的药物组合物，其生产方法以及在治疗细菌感染中的应用。

  公开号：

  US05696117A1
• 作为产物：
  描述：

  硝苯酚 在 palladium on activated charcoal 咪唑 、 氢气 、 potassium carbonate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、310.26 kPa 条件下， 反应 35.0h， 生成 2H-1,4-苯并噁嗪-3(4H)-酮,2-[2-[[(1,1-二甲基乙基)二甲基甲硅烷基]氧代]乙基]- 、 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  Benzoxazinones as PPARγ Agonists. 2. SAR of the Amide Substituent and In Vivo Results in a Type 2 Diabetes Model

  摘要：

  A series of benzoxazinones has been synthesized and tested for PPARgamma agonist activity. Synthetic approaches were developed to provide either racemic or chiral compounds. In vitro functional potency could be measured through induction of the aP2 gene, a target of PPARgamma. These studies revealed that compounds with large aliphatic chains at the nitrogen of the benzoxazinone were the most potent. Substitution of the chain was tolerated and in many cases enhanced the in vitro potency of the compound. Select compounds were further tested for metabolic stability, oral bioavailability in rats, and efficacy in db/db mice after 11 days of dosing. In vivo analysis with 13 and 57 demonstrated that the series has potential for the treatment of type 2 diabetes.

  DOI：

  10.1021/jm0301888

文献信息

• Benzoxazinones as PPARγ agonists. part 1: SAR of three aromatic regions
  作者：Philip J. Rybczynski、Roxanne E. Zeck、Donald W. Combs、Ignatius Turchi、Thomas P. Burris、Jun Z. Xu、Maria Yang、Keith T. Demarest

  DOI：10.1016/s0960-894x(03)00401-3

  日期：2003.7

  A series of benzoxazinones was synthesized as PPARgamma agonists. The compounds were obtained in seven steps, and SAR was developed by variations to the core shown below. The compounds were tested as functional agonists in the induction of the aP2 gene in preadipocytes, and the most potent compound in the series has an EC50=0.51 muM. The potency was further confirmed through a PPAR-Ga14 construct. Efficacy has been demonstrated in the db/db mouse model of hyperglycemia. (C) 2003 Elsevier Science Ltd. All rights reserved.
• Benzoxazinones as PPARγ Agonists. 2. SAR of the Amide Substituent and In Vivo Results in a Type 2 Diabetes Model
  作者：Philip J. Rybczynski、Roxanne E. Zeck、Joseph Dudash、Donald W. Combs、Thomas P. Burris、Maria Yang、Melville C. Osborne、Xiaoli Chen、Keith T. Demarest

  DOI：10.1021/jm0301888

  日期：2004.1.1

  A series of benzoxazinones has been synthesized and tested for PPARgamma agonist activity. Synthetic approaches were developed to provide either racemic or chiral compounds. In vitro functional potency could be measured through induction of the aP2 gene, a target of PPARgamma. These studies revealed that compounds with large aliphatic chains at the nitrogen of the benzoxazinone were the most potent. Substitution of the chain was tolerated and in many cases enhanced the in vitro potency of the compound. Select compounds were further tested for metabolic stability, oral bioavailability in rats, and efficacy in db/db mice after 11 days of dosing. In vivo analysis with 13 and 57 demonstrated that the series has potential for the treatment of type 2 diabetes.
• Benzoxazine antimicrobial agents
  申请人：Ortho Pharmaceutical Corporation

  公开号：US05696117A1

  公开（公告）日：1997-12-09

  The invention relates to benzoxazine and pyrido-oxazine antibacterial compounds of the general formula: ##STR1## wherein the moiety Q is a fused phenyl or fused pyridyl moiety as herein described, pharmaceutical compositions containing the compounds, methods for their production and their use in treating bacterial infections.

  该发明涉及一般式为：##STR1##的苯并噁嗪和吡啶噁嗪抗菌化合物，其中基团Q是如本文所述的融合苯或融合吡啶基团，含有这些化合物的药物组合物，其生产方法以及在治疗细菌感染中的应用。